Figure 7.

Anti-tumor activity of ch128.1/IgG1 in disseminated xenograft mouse models of MM. (A) SCID-Beige mice were challenged i.v. with 5 × 10⁶ KMS-11 cells and 2 or 9 days later treated i.v. with 100 μg ch128.1/IgG1. Mice were also challenged i.v. with 5 × 10⁶ (B) MM.1S or (C) MM.1R cells. cells. Two days after tumor challenge, mice were treated i.v. with 100 μg ch128.1/IgG1 or the ch128.1/IgG1 Fc mutant L234A/L235A/P329S. For each cell line (MM.1S and MM.1R), one group of mice was treated with 100 μg ch128.1/IgG1 9 days after tumor challenge. *p < 0.05, **p < 0.001, and ***p < 0.0001 (log-rank test). This figure was reproduced from Daniels-Wells et al. (163) with permission from Wolters Kluwer Health, Inc. The Creative Commons license does not apply to this content. Use of the material in any format is prohibited without written permission from the publisher, Wolters Kluwer Health, Inc. Please contact permissions@lww.com for further information.